Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

FluoGuide receives permission to start phase IIb trial in aggressive brain cancer

Copenhagen, Denmark, 30 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the company now has received the permission to start the phase IIb clinical trial with FG001.FluoGuide has now received approval from the Danish Ethical Committee and the trial can start in Denmark. FluoGuide announced in April FG001’s highly promising results in aggressive brain cancer (high grade glioma) following its phase I/IIa trial. FG001 was demonstrated to be well tolerated with only few patients reporting mild side effects (3 out of 40 patients). Furthermore, 100% of

Professor Kevin Eva is awarded the Karolinska Institutet Prize for Research in Medical Education

Prof. Kevin Eva is awarded the 2022 Karolinska Institutet Prize for Research in Medical Education (KIPRIME). Prof. Eva is Associate Director and Senior Scientist in the Centre for Health Education Scholarship, and Professor and Director of Educational Research and Scholarship in the Department of Medicine, at the University of British Columbia. He is also Editor-in-Chief of the journal Medical Education. Professor Eva’s work has greatly advanced health professions education research in many key areas and had a profound effect on an entire generation of educators and researchers.Professor

Cysec and Avassa partner up for automated, scalable, and secure edge computing environments

LAUSANNE, SWITZERLAND. and STOCKHOLM, SWEDEN. Cysec, a software provider for confidential computing, and Avassa, an edge application orchestration platform provider, enter a partnership to offer automated, scalable, and secure solutions for edge computing environments.For many enterprises today, it’s no longer a matter of cloud or edge — it’s a matter of both. And with a hybrid infrastructure, businesses need to apply tooling to stay innovative and efficient in both centralized and distributed environments. Cysec, a software provider for confidential computing, and Avassa, an edge

Platinum Egg brings popular Japanese Web 3.0 game to Concordium

August 30 - Zug, Switzerland - Tokyo, Japan -  Platinum Egg, the popular Japanese game company, has announced the upcoming integration of its Web 3.0 game, CrossLink , with the Concordium Blockchain.   With this partnership, Platinum Egg is making it easier for people with low cryptocurrency literacy to feel safe when joining the crypto space. “Another aspect of cryptocurrencies that has been preventing its widespread integration in Japan has been the perception of lack of security. A history of strict banking laws and regulations has created a

Altor supports H2 Green Steel on EUR 190 million funding round

Altor Fund V (Altor) continues to support the Swedish green impact company H2 Green Steel in its first close of the Series B equity financing. The key investors in the financing round next to Altor are AMF, GIC, Schaeffler, Swedbank Robur and Vargas Holding. Existing shareholders continue to support the company with additional equity funding, including such investors as Kingspan, FAM, Marcegaglia, IMAS Foundation, Cristina Stenbeck and Daniel Ek.Altor was also part of the initial Series A equity financing in March 2021.H2 Green Steel was founded in 2020 with the ambition to accelerate the

Changes in SkartaNYAB Plc's Executive Management Team

SkartaNYAB PlcCOMPANY ANNOUNCEMENT30 August 2022 at 10:00Changes in SkartaNYAB Plc’s Executive Management Team SkartaNYAB Plc has decided to reorganize management structures of the Finnish business operations of the group. Mikael Ritola starts as the Senior Vice President Finland as of 1 October 2022. He has previously been a member of the Executive Management Team of the group as Vice President Sweden, being responsible for special construction business in Sweden. Ritola is also a member of SkartaNYAB Plc’s Board of Directors. Mikko Ahonen, the previous Senior Vice President

Eficode achieves HashiCorp Specialized partner and Certified HashiCorp Implementation Partner statuses

Helsinki, August 30, 2022 - Eficode  has achieved HashiCorp Specialized partner status, and has also become a Certified HashiCorp Implementation Partner for HashiCorp Terraform and Vault. The partnership helps Eficode’s customers adopt a cloud operating model, upskill development teams, and move to modern cloud-based software development.Eficode offers HashiCorp Vault as part of its Eficode ROOT managed DevOps platform . Eficode customers have already included technologies from HashiCorp in their DevOps toolchains. Eficode also has

Read original

Scandion Oncology announce change to its Executive Management

Maj Hedtjärn has decided to resign from her position as Chief Operating Officer and Head of R&D Operations. She will leave Scandion Oncology no later than December 31, 2022.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces that Maj Hedtjärn, Chief Operating Officer, Head of R&D Operations and member of Executive Management, has decided to resign from her position to pursue new opportunities outside Scandion. Maj Hedtjärn will leave Scandion no later than December 31, 2022,

SkartaNYAB Plc's half-yearly report 1 January-30 June 2022: Profitable growth in Sweden - challenges in Finland

SkartaNYAB PlcCOMPANY ANNOUNCEMENT30 August 2022 at 09:55SkartaNYAB Plc’s half-yearly report 1 January–30 June 2022: Profitable growth in Sweden – challenges in Finland · The first combined quarter of Skarta and NYAB proved the successful merger of two Nordic companies, as good performance of Swedish business operations compensated challenges experienced in Finnish operations · The company has started measures to improve profitability in Finland during the rest of the year by utilizing practices that have been successful in Sweden, and is confident about successful future of the

Major shareholder announcement

Company announcement 36/2022 In accordance with section 30 of the Capital Markets Act, HusCompagniet A/S (the “Company”) hereby announces that Handelsbanken Fonder AB has notified the Company that Handelsbanken Fonder AB, directly and indirectly, holds less than 5.00% of the voting rights and shares in the Company. For additional information, please contact: HusCompagniet Cristina Rønde Hefting, Head of IR & Press                                                               +45 51 96 23 14 Information on HusCompagniet HusCompagniet is a leading provider of single-family

OmniCar Holding AB: OmniCar Holding AB: Omnicar Holding Q2 2022 report

Please find attached our Q2 2022 report Our ambitious growth plan continues to provide results with OmniCar reporting its strongest growth in the history of the company. · During the second quarter of 2022, revenue increased 260% sequentially to 21.1 million SEK from 5.9 million SEK in the first quarter of this year  · 383% revenue increase compared to Q2 2021 · OmniCarService continues its growth with revenue increasing 24% sequentially vs. 1Q22 and 125% YoY Investments in our technology, employees, and marketing are the driving force behind our growth this year. We will

Cantargia publishes preclinical data on strong anti-tumor efficacy of nadunolimab in combination with chemotherapy

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported publication of preclinical results demonstrating that Cantargia’s lead candidate, the IL1RAP-binding antibody nadunolimab (CAN04), shows synergistic anti-tumor efficacy with chemotherapy through a mechanism likely to be highly relevant in the clinical situation. The effect is dependent on the unique capability of nadunolimab to simultaneously block both the alpha and beta forms of interleukin-1 (IL-1). These findings support the promising clinical interim data observed with nadunolimab in pancreatic cancer (PDAC) and non-small

Mölnlycke[®] invests EUR 50 million in a new surgical gloves plant to meet future demand on supply and sustainability

Mölnlycke is investing EUR 50 million in a new plant in Kulim, Malaysia, to meet future demand for high-quality surgical gloves. The new plant will start production in September 2022 and will generate 500 new local job positions. With sustainable manufacturing as one of the main drivers for the initiative, Mölnlycke is partnering with ENGIE for energy solutions and Veolia Water Technologies for wastewater treatment solutions to ensure best-in-class energy and waste water management at the new plant.“The new plant is a key part of our future plans for sustainable growth within the surgical

Successful Meteor Live Firing with Gripen E

Saab recently conducted the first test firing with the advanced Meteor Beyond Visual Range Air-to-Air Missile (BVRAAM) on Gripen E with a successful end-to-end result on the target.The Meteor missile was launched from Gripen E at an altitude of approximately 16500 ft above the Vidsel test range in northern Sweden. “It feels very good that we have now completed the first test firing with Meteor from Gripen E. It is a very important milestone both for the programme and for Saab. It shows that the weapon capability of Gripen is at the absolute forefront,” says Mikael Olsson, Head of Flight

Scandinavian ChemoTech's subsidiary Vetiqure AB signs an exclusive distributor agreement for Turkey with Hasvet Medikal AS

Vetiqure AB has today signed an exclusive distributor agreement with Hasvet Medikal AS "Hasvet", which is the market leader in veterinary medicine in Turkey.Turkey, with its 84 million inhabitants, is one of Europe's absolute largest markets and thus has a very large potential despite the strained economic situation of the country. There are approximately 4 million cats and 2.5 million dogs in the country. Hasvet, which is basically a company that was started and is now run by veterinarians, has grown at a rapid pace and is today the major market leader of medical technology in

YEAR-END REPORT JULY 2021 – JUNE 2022

SELECTIMMUNE PHARMA IN SHORT · SelectImmune Pharma is an innovative biotech company that develops novel immunotherapies against infection. · Excessive innate immune responses to infection cause symptoms and pathology in acute pyelonephritis and acute cystitis. Immunomodulation is therefore a realistic option for treating these conditions as alternatives or complements to antibiotics. · Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including acute cystitis, severe kidney infection and urosepsis. · One

Cantargia publishes half year report

Cantargia AB’s (”Cantargia”) half year report for the period January until June 2022 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the second quarter · At ASCO 2022, one of the world’s largest cancer congresses, Cantargia presented interim clinical data for nadunolimab for the more than 100 patients with pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC) included in the phase IIa part of the CANFOUR study, and for the first patients in the CIRIFOUR study. · Positive preclinical efficacy data were

The Board of Directors of Swedish Stirling resolves on a new issue of preference shares of approximately SEK 100 million

The Board of Directors of Swedish Stirling AB (publ) ("Swedish Stirling" or the "Company") has today, by support of authorization from the annual general meeting on April 21, 2022, resolved to carry out an offering of newly issued climate-compensating[[1]] preference shares of approximately SEK 100 million (the “Offering”) to primarily finance the production and installation of PWR BLOK 400-F (“PWR BLOK”) at Glencore’s Lion smelter in Steelport, South Africa. As previously communicated by the Company, the Offering is supported by anchor investors Glencore International AG (“Glencore”), Merafe

Sedana Medical’s products receive MDR certification

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Medical Device Regulation (MDR) certification, which secures EU market access for Sedaconda® ACD under the new MDR regulation, well ahead of the deadline in 2024."The new EU Medical Device Regulation (MDR) was implemented to ensure an even higher level of quality and safety for medical devices in Europe. This approval is the final and very important step for Sedana Medical in the transition into the new regulation. Therefore, while this outcome was expected, I am proud of Sedana Medical’s efforts

BioStock: Elicera Therapeutics strengthens financial standing in Q2

During Q2, Elicera was awarded a major grant from the European Innovation Council Accelerator Programme for its lead CAR T-cell project ELC-301 and concluded preclinical proof-of-concept studies with oncolytic virus project ELC-201. Financial developments during the quarter now mean that Elicera can fully finance its clinical programme until the first half of 2024. The Swedish gene therapy company is now looking forward to key development milestones in its pursuit to bring new cancer treatments to market. BioStock got in touch with CEO Jamal El-Mosleh for a comment.Read the interview with

FREYR Battery Announces the Execution of 38 GWh Li-Ion Battery Binding Cell Sales Agreement and Entry into Module & Pack Joint Venture for Energy Storage Solutions with Nidec Corporation

Broad partnership with Nidec includes a firm sales contract to supply 38 GWh of next-generation clean LFP Li-Ion battery cells from 2025 - 2030 combined with a Joint Venture Agreement to develop, manufacture, and sell integrated, low carbon ESS solutions to industrial and utility grade customers· FREYR and Nidec have jointly agreed to convert and expand the previously announced 31 GWh conditional offtake agreement between the companies to a binding sales agreement under which FREYR will supply 38 GWh of cells from 2025 to 2030 with an option to upsize the volumes to 50 GWh in the period and

Betolar and Consolis Parma announce a partnership for low-carbon concrete testing in hollow-core slabs

Betolar Plc Press Release30.8.2022 Betolar and Consolis Parma announce a partnership for low-carbon concrete testing in hollow-core slabs Betolar has signed a development cooperation agreement to drive low-carbon construction with Consolis Parma, Finland's leading manufacturer of precast concrete elements. The aim is to test Betolar's solutions in the manufacturing of precast concrete elements and to significantly reduce emissions from the manufacturing phase of products.                      The development partnership creates new opportunities for Consolis Parma to

Farxiga shows CV mortality benefit across EF range

30 August 2022 07:01 BST New data show Farxiga significantly lowers the risk of cardiovascular death in patients with heart failure Pre-specified pooled analysis from Phase III trials demonstrated reduction in CV death by 14% and reduction in death from any cause by 10% in patients with heart failure irrespective of ejection fraction First heart failure medication to demonstrate mortality benefit across the full ejection fraction range Results being presented at the European Society of Cardiology annual meeting and simultaneously published in Nature Medicine Today, new

Farxiga reduced risk of CV death or worsening HF

30 August 2022 07:00 BST Farxiga significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of Farxiga in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64 million people Detailed results from the DELIVER Phase III trial

There are no items matching the current filter
There are no more items matching the current filter
Back to top